Загрузка...
Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiot...
Сохранить в:
| Опубликовано в: : | Case Rep Oncol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
S. Karger AG
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5903152/ https://ncbi.nlm.nih.gov/pubmed/29681813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487477 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|